Abstract
High Prevalence of BTK Mutations on Ibrutinib Therapy after 3 Years of Treatment in a Real-Life Cohort of CLL Patients: A Study from the French Innovative Leukemia Organization (FILO) Group
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have